Docetaxel-Carboplatin

ApprovedSmall molecule

NNational University Hospital, Singapore

Docetaxel-Carboplatin is one of 73 small molecule programs targeting Lung Cancer. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lung CancerActive, not recruiting

Breast CancerActive, not recruiting

Prostate CancerActive, not recruiting

Lung CancerApproved

Active, not recruiting

Breast CancerPreclinical

Active, not recruiting

Prostate CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Docetaxel-Carboplatin

NNational University Hospital, Singapore

Approved

1 2

Halaven

Eisai

Preclinical

38 3

Adriamycin

GGynecologic Oncology Group

Preclinical

87 4

Gemzar

GGynecologic Oncology Group

Preclinical

22 5

DATROWAY

Daiichi Sankyo

Preclinical

4 6

Megace

Bristol-Myers Squibb

Preclinical

4 7

Blenoxane

Bristol-Myers Squibb

Preclinical

1 8

Aquasol E

NNational Eye Institute (NEI)

Preclinical

—9

Zoladex

Luye Pharma Group Ltd.

Preclinical

8 10

Neoadjuvant Therapy

SSun Yat-sen University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Lung Cancer1 trial

Safety Study of Adjuvant Docetaxel-Carboplatin Treatment for Resected Lung Cancer

Completed·MMichael Mann·Phase 4·NCT00883675·133 enrolled

Prostate Cancer1 trial

A Phase II Study of Docetaxel Plus Carboplatin in Chemonaive Hormone-Refractory Prostate Cancer (HRPC) Patients

Completed·NNational University Hospital, Singapore·Phase 2·NCT00675545·2 enrolled

Breast Cancer1 trial

Predictors of Response to Neoadjuvant Docetaxel-Carboplatin Chemotherapy for Patients With Stage II and III Triple Negative Breast Cancer

Unknown status·MMiguel Martín Jiménez··NCT01560663·415 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Docetaxel-Carboplatin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Docetaxel-Carboplatin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Docetaxel-Carboplatin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National University Hospital, Singapore company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: NNational University Hospital, Singapore

Docetaxel-Carboplatin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Lung Cancer1 trial

Prostate Cancer1 trial

Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News